RxDoctor Payments Data

Zohar Yehoshua, MD

Retina Specialist · Miami, FLNPI 1407163041

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 52.5% of the total. That places this record below the midpoint for retina specialist clinicians in FL, where the typical reported total is $2,986.

$349in general payments, 2019–2025

Across 13 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$183
  • Astellas Pharma US Inc$35
  • Harrow Eye, LLC$31
  • AbbVie$31
  • Dompe US, Inc.$30
  • Rxsight Inc$20
  • plus $19 from 1 others
$401,249in research payments, 2019–2025

Across 86 payments — averaging $4665.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Apellis Pharmaceuticals, Inc.$401K

What the payments were for

  • Food & beverage$349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$349 in reported general payments places this provider in the 5th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$490,763
Medicare patients
920
Services billed
5,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine35$30,929
LumiganBimatoprost14$3,797
ZioptanTafluprost/Pf11$2,932
Ketorolac Tromethamine108$2,827
Prednisolone Acetate82$2,498
Timolol Maleate29$1,068
Latanoprost129$1,039
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat82$1,029
Atropine Sulfate11$780
Dorzolamide Hcl19$357
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha22$267
Brimonidine Tartrate21$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$31$34,72749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →